Elevated Serum ITGBL1 mRNA Expression: A Promising Diagnostic Tool for HBV-Associated Hepatocellular Carcinoma

Simple item page
AuthorNarges Arbabien
AuthorBita Moudien
AuthorZahra Heidarien
AuthorHamidreza Mahmoudzadeh-Sagheben
AuthorRoya Alavi-Nainien
AuthorZahra Saebi Nasaben
OrcidBita Moudi [0000-0001-6893-625X]en
OrcidZahra Heidari [0000-0002-3401-1619]en
OrcidHamidreza Mahmoudzadeh-Sagheb [0000-0002-3732-2586]en
OrcidRoya Alavi-Naini [0000-0002-9444-5224]en
Issued Date2025-12-31en
AbstractBackground: Hepatocellular carcinoma (HCC) accounts for 75 - 85% of primary liver cancers and is characterized by poor prognosis and low five-year survival rates, particularly in advanced stages. Chronic hepatitis B virus (HBV) infection is a major risk factor for HCC. Early detection of HBV-related HCC is crucial for improving patient outcomes; however, current surveillance methods such as ultrasonography and serum alpha-fetoprotein (AFP) testing have limited sensitivity. Objectives: This study aimed to evaluate serum mRNA expression of the biomarker integrin beta-like 1 (ITGBL1) in patients with HBV-related HCC, comparing it to patients with HBV infection only, HCC only, and healthy controls. Methods: In this cross-sectional case-control study, serum samples from 161 individuals (40 with HBV infection, 41 with HCC, 40 with early-stage HBV-related HCC, and 40 healthy controls) were analyzed. The ITGBL1 mRNA levels were quantified using quantitative real-time polymerase chain reaction (qRT-PCR), normalized to GAPDH. Clinical and biochemical parameters were also recorded and analyzed. Data were analyzed using SPSS version 20; analysis of variance (ANOVA) was used for group comparisons, with P < 0.05 considered significant. Results: The ITGBL1 mRNA expression was significantly elevated in the HBV-related HCC group compared to the HBV-only, HCC-only, and control groups (P < 0.01). Increased ITGBL1 expression was also observed in the HCC and HBV groups compared to controls (P < 0.05). Receiver operating characteristic (ROC) analysis showed excellent diagnostic performance for distinguishing HBV-related HCC from controls [area under the curve (AUC) = 0.82, sensitivity = 64.3%, specificity = 90.4%]. The biomarker demonstrated high diagnostic potential for differentiating HBV-related HCC from other groups. Clinical parameters, such as AFP levels, were markedly higher in the HCC and HBV-related HCC groups. No significant differences in age or gender distribution were found among the groups. Conclusions: This study highlights a strong association between ITGBL1 expression and HBV-related HCC, suggesting that serum ITGBL1 mRNA could serve as a sensitive and noninvasive biomarker for early diagnosis of HCC in HBV-infected patients. Its simplicity and reliability in serum samples make ITGBL1 a promising tool for monitoring patients at risk and improving early detection strategies. Limitations include the small sample size and a focus on early-stage HCC.en
DOIhttps://doi.org/10.5812/hepatmon-166059en
KeywordHepatocellular Carcinoma (HCC)en
KeywordHepatitis B Virus (HBV)en
KeywordIntegrin Beta-Like 1 (ITGBL1)en
KeywordBiomarkeren
KeywordEarly Diagnosisen
PublisherBrieflandsen
TitleElevated Serum ITGBL1 mRNA Expression: A Promising Diagnostic Tool for HBV-Associated Hepatocellular Carcinomaen
TypeResearch Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
hepatmon-25-1-166059-publish-pdf.pdf
Size:
394.81 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF
Download

Collections

Hepatitis Monthly